Global Photodynamic Therapy Market to Reach USD 7.48 Billion by 2033: Rising Demand in Cancer and Dermatology Drives Growth

Introduction

According to Renub Research Project Report photodynamic therapy (PDT) market is poised for strong growth, projected to reach USD 7.48 billion by 2033, up from USD 3.89 billion in 2024, representing a compound annual growth rate (CAGR) of 7.52% during 2025–2033. PDT is increasingly adopted for cancer treatment, dermatological disorders, and other medical applications, supported by innovations in light-based devices and photosensitizers.

Photodynamic therapy is a minimally invasive treatment that uses photosensitizing drugs activated by specific wavelengths of light to generate reactive oxygen species, selectively destroying abnormal cells while sparing healthy tissue. Its precision, non-invasive nature, and low side-effect profile make it an attractive alternative to conventional therapies.

Photodynamic Therapy Market Outlook

PDT is widely used in oncology for early-stage cancers, including esophageal, lung, and bladder cancers, as well as in dermatology for actinic keratosis, acne, and psoriasis. It also shows efficacy against drug-resistant bacterial infections. By targeting only diseased cells, PDT ensures minimal damage to healthy tissue, reduces recovery times, and improves patient quality of life.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Free Sample Report

Key Growth Drivers

Rising Prevalence of Cancer and Skin Disorders

The growing global incidence of cancers and dermatological disorders drives PDT demand. Cancer cases are projected to exceed 35 million by 2050, a 77% increase from 20 million in 2022, fueled by aging populations, lifestyle changes, and socioeconomic development. PDT offers targeted, minimally invasive therapy with fewer side effects compared to chemotherapy or surgery, making it increasingly preferred by patients and healthcare providers.

Technological Advancements in Light-Based Therapies

Innovations in LED, laser, and fiber-optic systems, coupled with next-generation photosensitizers, enhance treatment precision, depth of penetration, and biocompatibility. These advancements expand PDT applications and simplify procedures for healthcare facilities.

June 2024: Biofrontera Inc. launched RhodoLED XL, an FDA-approved red-light LED device with a user-friendly interface to advance PDT efficacy.

Research is ongoing to improve photosensitizer formulations and combination therapies, broadening PDT’s therapeutic scope.

Growing Demand for Non-Invasive Treatments

Patients increasingly favor non-invasive treatments with shorter recovery times and reduced hospital stays. PDT’s minimal tissue damage, outpatient suitability, and cost-effectiveness make it a popular option, especially for the aging population.

November 2024: Phase 3 clinical trial ALA-BCC-CT013 demonstrated statistically significant outcomes for sBCC patients using Ameluz with BF-RhodoLED.

Market Challenges

High Treatment Costs and Limited Reimbursement

PDT costs, including photosensitizers and specialized devices, can restrict adoption. Many countries lack comprehensive insurance coverage or reimbursement policies, particularly in developing regions, limiting patient access despite clinical efficacy.

Limited Awareness and Expertise

Many healthcare providers lack familiarity with PDT’s mechanisms, applications, and advantages over conventional therapies. Insufficient training programs hinder widespread adoption, reducing referrals and service availability. Educational initiatives and workshops are critical to bridging this knowledge gap.

Photodynamic Therapy Devices Market

PDT devices, such as lasers, LEDs, and fiber-optic systems, are essential for activating photosensitizers and delivering precise treatment. They are widely applied in oncology, dermatology, and ophthalmology. Market growth is fueled by technological innovation, increased awareness, and demand for non-invasive therapies, while high device costs and limited expertise remain constraints.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Regional Market Insights

United States

The U.S. leads the PDT devices market due to high cancer prevalence, dermatology cases, and advanced healthcare infrastructure. Clinical research, strong industry presence, and technological innovations support market expansion, although high costs and inconsistent reimbursement pose challenges.

Early 2024: Clinical trial for glioblastoma combining Pentalafen® and Heliance® laser device to evaluate intraoperative PDT at UPMC Hillman Cancer Center.

France

France shows steady PDT market growth, driven by oncology and dermatology adoption. A well-established healthcare system and government support facilitate expansion, though high costs and limited provider awareness remain barriers.

China

China’s PDT devices market benefits from a large patient population, increasing cancer incidence, and healthcare modernization initiatives.

May 2024: Photocure ASA’s partner, Asieris Pharmaceuticals, received NMPA acceptance for Cevira® (Hexaminolevulinate Hydrochloride PDT system) for non-surgical HSIL treatment.

Challenges include high costs, low provider awareness, and rural access limitations.

Brazil

Growing awareness of minimally invasive treatments in oncology and dermatology, coupled with improved healthcare infrastructure, drives Brazil’s PDT devices market. High device costs and limited rural access are constraints.

Saudi Arabia

Saudi Arabia experiences steady PDT growth due to skin disorder prevalence, cancer cases, and government support for advanced therapies. Device costs and provider awareness remain challenges, with future growth expected as education and infrastructure improve.

Market Segmentation

Product Type:

Photodynamic Therapy Devices

Photosensitizer Drugs

Applications:

Cancer

Actinic Keratosis

Psoriasis

Acne

Others

End Users:

Hospitals

Cosmetics & Dermatology Clinics

Cancer Treatment Centers

Others

Countries Covered:

North America: U.S., Canada

Europe: France, Germany, Italy, Spain, U.K., Belgium, Netherlands, Turkey

Asia Pacific: China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand

Latin America: Brazil, Mexico, Argentina

Middle East & Africa: Saudi Arabia, UAE, South Africa

Competitive Landscape

Key players include:

Gladerma S.A

Sun Pharmaceutical Industries Ltd

Biofrontera Inc.

Lumibird S.A

Bausch Health Companies Inc.

Soligenix Inc.

Modulight Corporation

Theralase Technologies Inc.

Companies focus on device innovation, FDA approvals, R&D in photosensitizers, and global market expansion to maintain competitive advantage.

Conclusion

The global photodynamic therapy market is expected to reach USD 7.48 billion by 2033, driven by rising cancer incidence, dermatological disorders, technological innovations, and patient preference for minimally invasive treatments.

Continued advancements in light-based devices, next-generation photosensitizers, and global awareness initiatives are expected to fuel adoption, creating opportunities for hospitals, clinics, and treatment centers worldwide. PDT’s precision, safety, and efficacy position it as a key player in next-generation cancer and dermatology therapies.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.